Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, California.
J Heart Lung Transplant. 2021 Sep;40(9):981-989. doi: 10.1016/j.healun.2021.05.022. Epub 2021 Jun 12.
Traditionally, implantation of Left Ventricular Assist Devices (LVADs) is performed via median sternotomy. Recently, less invasive thoracotomy approaches are growing in popularity as they involve less surgical trauma, potentially less bleeding, and may preserve right ventricular function. We hypothesized implantation of LVADs via thoracotomy has less perioperative right ventricular failure (RVF) and shorter postoperative length of stay (LOS).
Continuous flow LVAD implants from Intermacs between February 6, 2014 - December 31, 2018 were identified. Patients implanted via thoracotomy were propensity matched in a 1:1 ratio with patients implanted via sternotomy. Outcomes were compared between sternotomy and thoracotomy approach and by device type (axial, centrifugal-flow with hybrid levitation (CF-HL), centrifugal-flow with full magnetic levitation devices (CF-FML)). The primary outcome was time to first moderate or severe RVF. Secondary outcomes included survival and LOS.
Overall 978 thoracotomy patients were matched with 978 sternotomy patients. Over the study period, 242 thoracotomy patients and 219 sternotomy patients developed RVF with no significant difference in time to first moderate to severe RVF by surgical approach overall (p = 0.27) or within CF-HL (p = 0.36) or CF-FML devices (p = 0.25). Survival did not differ by implant technique (150 deaths in thoracotomy group, 154 deaths in sternotomy group; p = 0.58). However, sternotomy approach was associated with a significantly shorter LOS (17 Vs 18 days, p = 0.009).
As compared to sternotomy, implantation of continuous flow LVADs via thoracotomy approach does not reduce moderate to severe RVF or improve survival but does reduce post-operative LOS. Device type did not influence outcomes and most centers did a small volume of thoracotomy implants.
传统上,左心室辅助装置(LVAD)的植入是通过正中胸骨切开术进行的。最近,微创胸腔切开术越来越受欢迎,因为它们涉及的手术创伤较小,潜在的出血较少,并且可能保留右心室功能。我们假设通过胸腔切开术植入 LVAD 可减少围手术期右心室衰竭(RVF)并缩短术后住院时间(LOS)。
从 2014 年 2 月 6 日至 2018 年 12 月 31 日,确定了连续流动 LVAD 植入物的 Intermacs。通过胸腔切开术植入的患者与通过胸骨切开术植入的患者以 1:1 的比例进行倾向匹配。比较了胸骨切开术和胸腔切开术之间以及设备类型(轴流,混合悬浮式离心流(CF-HL),全磁悬浮离心流设备(CF-FML))的结果。主要结果是首次发生中度或重度 RVF 的时间。次要结果包括生存率和 LOS。
总体而言,有 978 例胸腔切开术患者与 978 例胸骨切开术患者相匹配。在整个研究期间,242 例胸腔切开术患者和 219 例胸骨切开术患者发生 RVF,在总体手术方法(p=0.27)或 CF-HL (p=0.36)或 CF-FML 装置(p=0.25)中,首次发生中度至重度 RVF 的时间无明显差异。手术技术的生存率无差异(胸腔切开术组 150 例死亡,胸骨切开术组 154 例死亡;p=0.58)。但是,胸骨切开术方法与较短的 LOS 显著相关(17 天与 18 天,p=0.009)。
与胸骨切开术相比,通过胸腔切开术植入连续流动 LVAD 并不会减少中重度 RVF 或改善生存率,但会缩短术后 LOS。设备类型并未影响结果,大多数中心的胸腔切开术植入量都较小。